Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases1

Canadian Journal of Physiology and Pharmacology

Volumn 92, Issue 7, 2014, Pages 558-565

  Parajuli, Nirmal ^a   Ramprasath, Tharmarajan ^a   Patel, Vaibhav B ^a   Wang, Wang ^a   Putko, Brendan ^a   Mori, Jun ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Ace2; Heart failure; Renin angiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN;

ANIMAL; HEART FAILURE; HUMAN; HYPERTENSION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; HEART FAILURE; HUMANS; HYPERTENSION; PEPTIDYL-DIPEPTIDASE A; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84903292649     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2013-0488     Document Type: Review

References (92)

1. Bader, M. 2013. ACE2, angiotensin-(1-7), and Mas: the other side of the coin. Pflugers Arch. 465(1): 79-85. doi:10.1007/s00424-012-1120-0. PMID:23463883.
2. Benter, I.F., Yousif, M.H., Cojocel, C., Al-Maghrebi, M., and Diz, D.I. 2007. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292(1): H666-H672. doi:10.1152/ajpheart.00372.2006. PMID:17213482.
3. Bindom, S.M., Hans, C.P., Xia, H., Boulares, A.H., and Lazartigues, E. 2010. Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes, 59(10): 2540-2548. doi:10.2337/db09-0782. PMID:20660625.
4. Bodiga, S., Zhong, J.C., Wang, W., Basu, R., Lo, J., Liu, G.C., et al. 2011. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit. Cardiovasc. Res. 91(1): 151-161. doi:10.1093/cvr/cvr036. PMID:21285291.
5. Bui, A.L., Horwich, T.B., and Fonarow, G.C. 2011. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8(1): 30-41. doi:10.1038/nrcardio.2010.165. PMID:21060326.
6. Burrell, L.M., Johnston, C.I., Tikellis, C., and Cooper, M.E. 2004. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol. Metab. 15(4): 166-169. doi:10.1016/j.tem.2004.03.001. PMID:15109615.
7. Burrell, L.M., Risvanis, J., Kubota, E., Dean, R.G., MacDonald, P.S., Lu, S., et al. 2005. Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J. 26(4): 369-375; discussion 322-364. doi:10.1093/eurheartj/ehi114. PMID:15671045.
8. Burrell, L.M., Burchill, L., Dean, R.G., Griggs, K., Patel, S.K., and Velkoska, E. 2012. Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp. Physiol. 97(4): 477-485. doi:10.1113/expphysiol.2011.063156. PMID:22198016.
9. Burrell, L.M., Harrap, S.B., Velkoska, E., and Patel, S.K. 2013. The ACE2 gene: its potential as a functional candidate for cardiovascular disease. Clin. Sci. (Lond.), 124(2): 65-76. doi:10.1042/CS20120269. PMID:23013041.
10. Chappell, M.C. 2007. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension, 50(4): 596-599. doi:10.1161/HYPERTENSIONAHA. 106.076216. PMID:17785634.
11. Clarke, N.E., Belyaev, N.D., Lambert, D.W., and Turner, A.J. 2014. Epigenetic regulation of angiotensin converting enzyme-2 (ACE2) by SIRT1 under conditions of cell energy stress. Clin. Sci. (Lond.), 126(7): 507-516. doi:10.1042/ CS20130291. PMID:24147777.
12. Crackower, M.A., Sarao, R., Oudit, G.Y., Yagil, C., Kozieradzki, I., Scanga, S.E., et al. 2002. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature, 417(6891): 822-828. doi:10.1038/nature00786. PMID: 12075344.
13. Danser, A.H., and Schalekamp, M.A. 1996. Is there an internal cardiac renin- angiotensin system? Heart, 76(3 Suppl. 3): 28-32. doi:10.1136/hrt.76.3_ Suppl_3.28. PMID:8983664.
14. Der Sarkissian, S., Huentelman, M.J., Stewart, J., Katovich, M.J., and Raizada, M.K. 2006. ACE2: A novel therapeutic target for cardiovascular diseases. Prog. Biophys. Mol. Biol. 91(1-2): 163-198. doi:10.1016/j.pbiomolbio. 2005.05.011. PMID:16009403.
15. Der Sarkissian, S., Grobe, J.L., Yuan, L., Narielwala, D.R., Walter, G.A., Katovich, M.J., and Raizada, M.K. 2008. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension, 51(3): 712-718. doi:10.1161/HYPERTENSIONAHA. 107.100693. PMID:18250366.
16. Di Lisa, F., Kaludercic, N., and Paolocci, N. 2011. Beta(2)-adrenoceptors, NADPH oxidase, ROS and p38 MAPK: another 'radical' road to heart failure? Br. J. Pharmacol. 162(5): 1009-1011. doi:10.1111/j.1476-5381.2010.01130.x. PMID:21271996.
17. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., et al. 2000. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87(5): E1-E9. doi:10.1161/01.RES.87.5.e1. PMID:10969042.
18. Donoghue, M., Wakimoto, H., Maguire, C.T., Acton, S., Hales, P., Stagliano, N., et al. 2003. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J. Mol. Cell. Cardiol. 35(9): 1043-1053. doi:10.1016/S0022-2828(03)00177-9. PMID:12967627.
19. Ebermann, L., Spillmann, F., Sidiropoulos, M., Escher, F., Heringer-Walther, S., Schultheiss, H.P., et al. 2008. The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur. J. Pharmacol. 590(1-3): 276-280. doi:10.1016/j.ejphar.2008.05.024. PMID:18571157.
20. Ecder, T., Korular, D., Gurevich, A.K., Weinberger, H.D., and Schrier, R.W. 2001. Therapy of heart failure. Curr. Opin. Investig. Drugs, 2(1): 81-86. PMID: 11527017.
21. Epelman, S., Tang, W.H., Chen, S.Y., Van Lente, F., Francis, G.S., and Sen, S. 2008. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the reninangiotensin- aldosterone system. J. Am. Coll. Cardiol. 52(9): 750-754. doi:10.1016/j.jacc.2008.02.088. PMID:18718423.
22. Epelman, S., Shrestha, K., Troughton, R.W., Francis, G.S., Sen, S., Klein, A.L., and Tang, W.H. 2009. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J. Card. Fail. 15(7): 565-571. doi:10.1016/j.cardfail.2009.01.014. PMID:19700132.
23. Feng, Y., Yue, X., Xia, H., Bindom, S.M., Hickman, P.J., Filipeanu, C.M., et al. 2008. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ. Res. 102(6): 729-736. doi:10.1161/CIRCRESAHA.107.169110. PMID:18258853.
24. Feng, Y., Xia, H., Cai, Y., Halabi, C.M., Becker, L.K., Santos, R.A., et al. 2010. Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ. Res. 106(2): 373-382. doi:10.1161/CIRCRESAHA.109.208645. PMID:19926873.
25. Feng, Y., Hans, C., McIlwain, E., Varner, K.J., and Lazartigues, E. 2012. Angiotensinconverting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy. PloS One, 7(11): e48910. doi:10.1371/journal.pone.0048910. PMID:23155428.
26. Fernandes, T., Hashimoto, N.Y., Magalhaes, F.C., Fernandes, F.B., Casarini, D.E., Carmona, A.K., et al. 2011. Aerobic exercise training-induced left ventricular hypertrophy involves regulatory microRNAs, decreased angiotensin-converting enzyme-angiotensin II, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7). Hypertension, 58(2): 182-189. doi:10.1161/HYPERTENSIONAHA.110.168252. PMID:21709209.
27. Ferrario, C.M., Jessup, J., Chappell, M.C., Averill, D.B., Brosnihan, K.B., Tallant, E.A., et al. 2005. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation, 111(20): 2605-2610. doi:10.1161/CIRCULATIONAHA.104. 510461. PMID:15897343.
28. Ferreira, A.J., Jacoby, B.A., Araujo, C.A., Macedo, F.A., Silva, G.A., Almeida, A.P., et al. 2007. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 292(2): H1113-H1119. doi:10.1152/ajpheart.00828.2006. PMID:17056670.
29. Flores-Munoz, M., Godinho, B.M., Almalik, A., and Nicklin, S.A. 2012. Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the Mas or angiotensin type 2 receptor. PloS One, 7(9): e45564. doi:10.1371/journal.pone.0045564. PMID:23029101.
30. Goncalves, R. 1999. Diastolic heart failure: identification and characterization. Epidemiology, prevalence and grounds for clinical suspicion. Rev. Port. Cardiol. 18(Suppl. 5): V17-V18. PMID:10582450.
31. Goulter, A.B., Goddard, M.J., Allen, J.C., and Clark, K.L. 2004. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2: 19. doi:10.1186/ 1741-7015-2- 9. PMID:15151696.
32. Gwathmey, T.M., Pendergrass, K.D., Reid, S.D., Rose, J.C., Diz, D.I., and Chappell, M.C. 2010. Angiotensin-(1-7) - angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension, 55(1): 166-171. doi:10.1161/HYPERTENSIONAHA.109.141622. PMID:19948986.
33. Gwathmey, T.M., Alzayadneh, E.M., Pendergrass, K.D., and Chappell, M.C. 2012. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302(5): R518-R530. doi:10.1152/ ajpregu.00525.2011. PMID:22170620.
34. Hamming, I., Cooper, M.E., Haagmans, B.L., Hooper, N.M., Korstanje, R., Osterhaus, A.D., et al. 2007. The emerging role of ACE2 in physiology and disease. J. Pathol. 212(1): 1-11. doi:10.1002/path.2162. PMID:17464936.
35. Iwai, M., Nakaoka, H., Senba, I., Kanno, H., Moritani, T., and Horiuchi, M. 2012. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II type 1 receptor blockade on vascular remodeling. Hypertension, 60(1): 137-144. doi:10.1161/HYPERTENSIONAHA. 112.191452. PMID:22665126.
36. Keidar, S., Gamliel-Lazarovich, A., Kaplan, M., Pavlotzky, E., Hamoud, S., Hayek, T., et al. 2005. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ. Res. 97(9): 946-953. doi:10.1161/01.RES.0000187500.24964.7A. PMID:16179584.
37. Keidar, S., Kaplan, M., and Gamliel-Lazarovich, A. 2007. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc. Res. 73(3): 463-469. doi:10.1016/ j.cardiores.2006.09.006. PMID:17049503.
38. Kemp, C.D., and Conte, J.V. 2012. The pathophysiology of heart failure. Cardiovasc. Pathol. 21(5): 365-371. doi:10.1016/j.carpath.2011.11.007. PMID:22227365.
39. Kittleson, M.M., Minhas, K.M., Irizarry, R.A., Ye, S.Q., Edness, G., Breton, E., et al. 2005. Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol. Genomics, 21(3): 299-307. doi:10.1152/physiolgenomics.00255.2004. PMID: 15769906.
40. Li, G., Liu, Y., Zhu, Y., Liu, A., Xu, Y., Li, X., et al. 2013. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung, 191(4): 327-336. doi:10. 1007/s00408-013-9470-8. PMID:23652350.
41. Li, M., Liu, K., Michalicek, J., Angus, J.A., Hunt, J.E., Dell'Italia, L.J., et al. 2004. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J. Clin. Invest. 114(1): 112-120. doi:10.1172/JCI200420805. PMID:15232618.
42. Liu, C., Lv, X.H., Li, H.X., Cao, X., Zhang, F., Wang, L., et al. 2012. Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes. Acta Diabetol. 49(4): 291-299. doi:10.1007/s00592-011-0348-z. PMID:22042130.
43. Liu, J., Ji, H., Zheng, W., Wu, X., Zhu, J.J., Arnold, A.P., and Sandberg, K. 2010. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-dependent and sex chromosome-independent. Biol. Sex Differ. 1(1): 6. doi:10.1186/2042-6410-1-6. PMID:21208466.
44. Lo, J., Patel, V.B., Wang, Z., Levasseur, J., Kaufman, S., Penninger, J.M., and Oudit, G.Y. 2013. Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. Exp. Physiol. 98(1): 109-122. doi:10.1113/expphysiol.2012.067165. PMID:22750422.
45. Loot, A.E., Roks, A.J., Henning, R.H., Tio, R.A., Suurmeijer, A.J., Boomsma, F., and van Gilst, W.H. 2002. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation, 105(13): 1548-1550. doi:10.1161/01.CIR.0000013847.07035.B9. PMID:11927520.
46. Lovren, F., Pan, Y., Quan, A., Teoh, H., Wang, G., Shukla, P.C., et al. 2008. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 295(4): H1377-H1384. doi: 10.1152/ajpheart.00331.2008. PMID:18660448.
47. Maione, A., Navaneethan, S.D., Graziano, G., Mitchell, R., Johnson, D., Mann, J.F., et al. 2011. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol. Dial. Transplant. 26(9): 2827-2847. doi:10.1093/ndt/ gfq792. PMID:21372254.
48. McMurray, J.J. 2010. Clinical practice. Systolic heart failure. N. Engl. J. Med. 362(3): 228-238. doi:10.1056/NEJMcp0909392. PMID:20089973.
49. McMurray, J.J. 2011. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur. J. Heart Fail. 13(9): 929-936. doi:10.1093/eurjhf/hfr093. PMID:21816763.
50. Miceli, A., Capoun, R., Fino, C., Narayan, P., Bryan, A.J., Angelini, G.D., and Caputo, M. 2009. Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol. 54(19): 1778-1784. doi:10.1016/j.jacc.2009.07.008. PMID: 19682819.
51. Mori, J., Zhang, L., Oudit, G.Y., and Lopaschuk, G.D. 2013. Impact of the renin- angiotensin system on cardiac energy metabolism in heart failure. J. Mol. Cell. Cardiol. 63: 98-106. doi:10.1016/j.yjmcc.2013.07.010. PMID:23886814.
52. Mosterd, A., and Hoes, A.W. 2007. Clinical epidemiology of heart failure. Heart, 93(9): 1137-1146. doi:10.1136/hrt.2003.025270. PMID:17699180.
53. Murca, T.M., Almeida, T.C., Raizada, M.K., and Ferreira, A.J. 2012. Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from ardiovascular autonomic dysfunction. Exp. Physiol. 97(6): 699-709. doi:10.1113/expphysiol.2011.063461. PMID:22286369.
54. Murray-Thomas, T., and Cowie, M.R. 2003. Epidemiology and clinical aspects of congestive heart failure. J. Renin Angiotensin Aldosterone Syst. 4(3): 131-136. doi:10.3317/jraas.2003.020. PMID:14608515.
55. Oudit, G.Y., and Penninger, J.M. 2011. Recombinant human angiotensinconverting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr. Heart Fail. Rep. 8(3): 176-183. doi:10.1007/s11897-011- 0063-7. PMID:21611889.
56. Oudit, G.Y., Crackower, M.A., Backx, P.H., and Penninger, J.M. 2003. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc. Med. 13(3): 93-101. doi:10.1016/S1050-1738(02)00233-5. PMID:12691672.
57. Oudit, G.Y., Kassiri, Z., Patel, M.P., Chappell, M., Butany, J., Backx, P.H., et al. 2007. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 75(1): 29-39. doi:10.1016/j.cardiores.2007.04.007. PMID:17499227.
58. Oudit, G.Y., Kassiri, Z., Jiang, C., Liu, P.P., Poutanen, S.M., Penninger, J.M., and Butany, J. 2009. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Invest. 39(7): 618-625. doi:10.1111/j.1365-2362.2009.02153.x. PMID:19453650.
59. Patel, V.B., Bodiga, S., Fan, D., Das, S.K., Wang, Z., Wang, W., et al. 2012. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensinconverting enzyme 2-null mice. Hypertension, 59(6): 1195-1203. doi:10.1161/ HYPERTENSIONAHA.112.191650. PMID:22508831.
60. Patel, V.B., Clarke, N., Wang, Z., Fan, D., Parajuli, N., Basu, R., et al. 2014. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. J. Mol. Cell. Cardiol. 66: 167-176. doi:10.1016/j.yjmcc.2013.11.017. PMID:24332999.
61. Paul, M., Wagner, J., and Dzau, V.J. 1993. Gene expression of the renin- angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J. Clin. Invest. 91(5): 2058-2064. doi:10.1172/JCI116428. PMID:8387539.
62. Paul, M., Poyan Mehr, A., and Kreutz, R. 2006. Physiology of local renin- angiotensin systems. Physiol. Rev. 86(3): 747-803. doi:10.1152/physrev.00036. 2005. PMID:16816138.
63. Perlot, T., and Penninger, J.M. 2013. ACE2 - From the renin-angiotensin system to gut microbiota and malnutrition. Microbes Infect. 15(13): 866-873. doi:10.1016/j.micinf.2013.08.003. PMID:23962453.
64. Philbin, E.F., Rocco, T.A., Jr., Lindenmuth, N.W., Ulrich, K., and Jenkins, P.L. 2000. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am. J. Med. 109(8): 605-613. doi:10.1016/S0002-9343(00)00601-X. PMID: 11099679.
65. Qi, Y., Shenoy, V., Wong, F., Li, H., Afzal, A., Mocco, J., et al. 2011. Lentivirusmediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. Exp. Physiol. 96(9): 863-874. doi:10.1113/expphysiol. 2011.056994. PMID:21685447.
66. Rentzsch, B., Todiras, M., Iliescu, R., Popova, E., Campos, L.A., Oliveira, M.L., et al. 2008. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension, 52(5): 967-973. doi:10.1161/HYPERTENSIONAHA.108.114322. PMID:18809792.
67. Roger, V.L. 2013. Epidemiology of heart failure. Circ. Res. 113(6): 646-659. doi: 10.1161/CIRCRESAHA.113.300268. PMID:23989710.
68. Santos, R.A., Simoes e Silva, A.C., Maric, C., Silva, D.M., Machado, R.P., de Buhr, I., et al. 2003. Angiotensin-(1-7) is an endogenous ligand for the G proteincoupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100(14): 8258-8263. doi:10.1073/pnas.1432869100. PMID:12829792.
69. Sato, T., Suzuki, T., Watanabe, H., Kadowaki, A., Fukamizu, A., Liu, P.P., et al. 2013. Apelin is a positive regulator of ACE2 in failing hearts. J. Clin. Invest. 123(12): 5203-5211. doi:10.1172/JCI69608. PMID:24177423.
70. Schrier, R.W., Abdallah, J.G., Weinberger, H.H., and Abraham, W.T. 2000. Therapy of heart failure. Kidney Int. 57(4): 1418-1425. doi:10.1046/j.1523-1755.2000.00986.x. PMID:10760077.
71. Shah, A.M., and Mann, D.L. 2011. Heart failure. 1. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet, 378(9792): 704-712. doi:10.1016/S0140-6736(11)60894-5. PMID:21856484.
72. Simoes e Silva, A.C., Silveira, K.D., Ferreira, A.J., and Teixeira, M.M. 2013. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol. 169(3): 477-492. doi:10.1111/bph.12159. PMID:23488800.
73. Song, B., Jin, H., Yu, X., Zhang, Z., Yu, H., Ye, J., et al. 2013. Angiotensinconverting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAPK signaling pathways. Regul. Pept. 185C: 44-51. doi:10.1016/j.regpep.2013.06.007. PMID:23816468.
74. Swedberg, K., Eneroth, P., Kjekshus, J., and Wilhelmsen, L. 1990. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation, 82(5): 1730-1736. doi:10.1161/01.CIR.82.5.1730. PMID:2225374.
75. Thallas-Bonke, V., Coughlan, M.T., Bach, L.A., Cooper, M.E., and Forbes, J.M. 2010. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy. Am. J. Nephrol. 32(1): 73-82. doi:10.1159/000314924. PMID:20551625.
76. Tipnis, S.R., Hooper, N.M., Hyde, R., Karran, E., Christie, G., and Turner, A.J. 2000. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275(43): 33238-33243. doi:10.1074/jbc.M002615200. PMID:10924499.
77. Wang, W., Bodiga, S., Das, S.K., Lo, J., Patel, V., and Oudit, G.Y. 2011. Role of ACE2 in diastolic and systolic heart failure. Heart Fail. Rev. 17(4): 683-691. doi:10.1007/s10741-011-9259-x. PMID:21638102.
78. Warner, F.J., Lew, R.A., Smith, A.I., Lambert, D.W., Hooper, N.M., and Turner, A.J. 2005. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J. Biol. Chem. 280(47): 39353-39362. doi:10.1074/jbc.M508914200. PMID:16166094.
79. Wei, C.C., Hase, N., Inoue, Y., Bradley, E.W., Yahiro, E., Li, M., et al. 2010. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J. Clin. Invest. 120(4): 1229-1239. doi:10.1172/JCI39345. PMID:20335663.
80. Wei, Y., Sowers, J.R., Clark, S.E., Li, W., Ferrario, C.M., and Stump, C.S. 2008. Angiotensin II-induced skeletal muscle insulin resistance mediated by NFkappaB activation via NADPH oxidase. Am. J. Physiol. Endocrinol. Metab. 294(2): E345-E351. doi:10.1152/ajpendo.00456.2007. PMID:18073321.
81. Wiseman, W., Egan, J.M., Slemmer, J.E., Shaughnessy, K.S., Ballem, K., Gottschall-Pass, K.T., and Sweeney, M.I. 2011. Feeding blueberry diets inhibits angiotensin II-converting enzyme (ACE) activity in spontaneously hypertensive stroke-prone rats. Can. J. Physiol. Pharmacol. 89(1): 67-71. doi:10.1139/Y10- 101. PMID:21186379.
82. Wysocki, J., Ye, M., Rodriguez, E., Gonzalez-Pacheco, F.R., Barrios, C., Evora, K., et al. 2010. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension, 55(1): 90-98. doi:10.1161/HYPERTENSIONAHA. 109.138420. PMID:19948988.
83. Xia, H., and Lazartigues, E. 2008. Angiotensin-converting enzyme 2 in the brain: properties and future directions. J. Neurochem. 107(6): 1482-1494. doi:10.1111/ j.1471-4159.2008.05723.x. PMID:19014390.
84. Xia, H., Suda, S., Bindom, S., Feng, Y., Gurley, S.B., Seth, D., et al. 2011. ACE2- mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PloS One, 6(7): e22682. doi:10.1371/journal.pone.0022682. PMID:21818366.
85. Yamamoto, K., Ohishi, M., Katsuya, T., Ito, N., Ikushima, M., Kaibe, M., et al. 2006. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension, 47(4): 718-726. doi:10.1161/01.HYP.0000205833.89478.5b. PMID: 16505206.
86. Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Jr., Drazner, M.H., et al. 2013. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 128(16): e240-e319. doi:10.1161/CIR.0b013e31829e8776. PMID:23741058.
87. Yusuf, S., Reddy, S., Ounpuu, S., and Anand, S. 2001a. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation, 104(22): 2746-2753. doi:10.1161/hc4601.099487. PMID:11723030.
88. Yusuf, S., Reddy, S., Ounpuu, S., and Anand, S. 2001b. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation, 104(23): 2855-2864. doi:10.1161/hc4701.099488. PMID:11733407.
89. Zhang, C., Zhao, Y.X., Zhang, Y.H., Zhu, L., Deng, B.P., Zhou, Z.L., et al. 2010. Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc. Natl. Acad. Sci. U.S.A. 107(36): 15886-15891. doi:10.1073/pnas.1001253107. PMID:20798044.
90. Zhong, J.C., Yu, X.Y., Lin, Q.X., Li, X.H., Huang, X.Z., Xiao, D.Z., and Lin, S.G. 2008. Enhanced angiotensin converting enzyme 2 regulates the insulin/Akt signalling pathway by blockade of macrophage migration inhibitory factor expression. Br. J. Pharmacol. 153(1): 66-74. doi:10.1038/sj.bjp.0707482. PMID: 17906677.
91. Zhong, J., Basu, R., Guo, D., Chow, F.L., Byrns, S., Schuster, M., et al. 2010. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation, 122(7): 717-728. doi:10.1161/CIRCULATIONAHA.110.955369. PMID:20679547.
92. Zhong, J.C., Ye, J.Y., Jin, H.Y., Yu, X., Yu, H.M., Zhu, D.L., et al. 2011. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul. Pept. 166(1-3): 90-97. doi:10.1016/j.regpep.2010.09.005. PMID:20854846.